| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (NCT05138458) | Myeloid Therapeutics | 2021-12-15 |
| A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin (NCT04998331) | Takeda | 2021-10-29 |
| A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) (NCT05137847) | Eisai Inc. | 2021-05-24 |
| Study of Photopheresis in the Treatment of Erythrodermic MF and SS (NCT03563040) | European Organisation for Research and Treatment of Cancer - EORTC | 2020-12-01 |
| Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides (NCT03789864) | Indiana University | 2019-10-07 |
| Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma (NCT03742804) | Yale University | 2019-06-01 |
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (NCT03902184) | Innate Pharma | 2019-05-22 |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders (NCT03601819) | University of Michigan Rogel Cancer Center | 2019-05-15 |
| PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) (NCT03357224) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-09-24 |
| Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (NCT03302728) | Peter MacCallum Cancer Centre, Australia | 2018-08-30 |
| CTCL Directed Therapy (NCT03116659) | James J. Peters Veterans Affairs Medical Center | 2018-02-01 |
| AFM13 in Relapsed/Refractory Cutaneous Lymphomas (NCT03192202) | Ahmed Sawas | 2017-07-17 |
| Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL (NCT02811783) | Elorac, Inc. | 2017-01-01 |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (NCT02953301) | 4SC AG | 2016-11-01 |
| AEDV Registry of Primary Cutaneous Lymphoma (NCT03646422) | Fundación Academia Española de Dermatología | 2016-09-01 |
| Tissue Repository: CTCL Collection Protocol (NCT02840747) | Columbia University | 2016-07-01 |
| VircapSeq Virus Detection in Sézary Syndrome (NCT02836886) | Columbia University | 2016-06-01 |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma (NCT02567656) | Rhizen Pharmaceuticals SA | 2015-09-01 |
| Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas (NCT02181218) | Washington University School of Medicine | 2015-02-04 |
| Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas (NCT02323659) | Polish Lymphoma Research Group | 2014-06-01 |
| Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) (NCT01433731) | TetraLogic Pharmaceuticals | 2011-11-01 |
| Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma (NCT00896493) | Stanford University | 2009-05-01 |
| CPG 7909 in Patients With Cutaneous T-Cell Lymphoma (NCT00043420) | Pfizer | 2003-01-01 |
| Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) (NCT00211198) | Eisai Inc. | 2001-05-01 |
| Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients (NCT00050999) | Eisai Inc. | 1995-06-01 |
| A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies (NCT00051597) | Seagen Inc. | |
| A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 (NCT01196208) | Seagen Inc. | |
| Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) (NCT00419367) | Merck Sharp & Dohme LLC | |